“Rokit Healthcare’s Skin Regeneration Technology Launches in US Market with Exclusive Supply Contract with Tides Medical”

[앵커]

Rokit Healthcare’s skin regeneration platform will be launched in the world’s largest medical market, the United States.
Ahead of full-scale commercialization, Tides Medical, which signed an exclusive supply contract in the US, visited Korea to discuss supply plans. Reporter Kim Hyo-sun reports.

[기자]

In the field of skin regeneration, ‘diabetic foot disease’ is the most difficult to treat.
Rokit Healthcare’s skin regeneration platform uses tissue extracted from the patient’s body as a material for bio-ink, and it is attracting attention as a new treatment in the field of skin regeneration medicine, especially as it can be used right away in the operating room.

photo-layout image photo_151560 max-width-600 float-center" data-idxno="151560" data-type="photo" style="display:inline-block">

[Doug Payne/ Tides Medical COO]

“I think (Rokit Healthcare’s technology) is very innovative. (Rokit) understands that every patient is different and uses the power of regenerative medicine and personalized methods. It is very innovative and we can bring this technology to the US. We are proud of our partners.”

photo-layout image photo_151564 max-width-600 float-center" data-idxno="151564" data-type="photo" style="display:inline-block">

In particular, the company signed an exclusive sales contract in the US with Tiz Medical, a US bio-healthcare company, in April.

photo-layout image photo_151561 max-width-600 float-center" data-idxno="151561" data-type="photo" style="display:inline-block">

[김지희/ 로킷헬스케어 CTO&피부재생플랫폼 부서 사장]
“Because Rokit Healthcare was the first company in the world to use high-tech technologies in front of patients in hospitals, Tiz Medical in the US signed a contract with us to spread regenerative treatment technology to the US for the first time. Goyo. With this technology, we plan to use it to treat skin diseases and diabetic foot patients for the first time.”

Currently, 12% of the entire US population is diabetic, and one in 20 seconds has a leg amputated due to lack of effective treatment. Tiz Medical plans to provide new treatment technology through Rokit Healthcare’s technology and aims to treat 30,000 patients by 2025.

photo-layout image photo_151562 max-width-600 float-center" data-idxno="151562" data-type="photo" style="display:inline-block">

[Joe Spell/ Tides Medical CEO]
“We believe there will be a long-term collaboration with Rokit and we will be able to treat many of the 4 million patients in the US who currently do not receive any treatment. Our plant is a small business in a center of excellence facilities renowned for its expertise and “We’re just starting out and figuring out exactly how it works in the U.S. healthcare system. Next year we’re planning a much broader rollout and we’ll be able to get it to more clinicians.”

In addition, through this supply, the company aims to secure a market share of more than 10% in the US diabetic foot market, and is confident of securing more than 30% of sales.

photo-layout image photo_151563 max-width-600 float-center" data-idxno="151563" data-type="photo" style="display:inline-block">

[유석환/ 로킷헬스케어 회장]
“Since the US accounts for about 25% of our global market, we are looking at whether the contract will increase sales by 2-30%.”

This is Kim Hyo-sun from Pax Economy TV.

Copyright © Pax Economy TV Unauthorized reproduction and redistribution prohibited